•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Advair
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


AddThis Social Bookmark Button
DOWNLOAD OUR INFORMATION PACKAGE

Injured by Advair?

The Advair Diskus inhaler contains a combination of fluticasone and salmeterol and is used to treat asthma. Fluticasone and salmeterol shrink the swelling in the airways and relax and open air passages in the lungs. Advair was approved in 2000, by the FDA and is made by GlaxoSmithKline.

The FDA, on November 15, 2005 issued a public health advisory about potentially fatal side effects from two GlaxoSmithKline asthma drugs. The agency is asking the maker of the drugs, Advair Diskus and Serevent Diskus, to add warnings to their labels that these medications "may increase the chance of severe asthma episodes, and death when those episodes occur."

Advair is GlaxoSmithKline's biggest product, with $4 billion in sales during the first nine months of 2005. Serevent's sales were $450 million. Advair is a long-acting beta 2-adrenergic agonist, or LABA, which provides asthma relief by relaxing muscles around the airways to the lungs. Although they can reduce the number of asthma episodes, the FDA says they "may increase the chances of a severe asthma episode when they do occur."

In one study, the agency says, "an increased number of people taking a LABA in addition to their usual asthma care died from their asthma compared to people taking a placebo in addition to their usual asthma care, although the number of asthma deaths in the study was small."

In August 2003, the FDA announced the addition of new safety information and warnings to the labeling for drug products that contain salmeterol. The new labeling includes a boxed warning about a small, but significant, increased risk of life-threatening asthma episodes or asthma-related deaths observed in patients taking salmeterol in a recently completed large U.S. safety study.

Advair Label Update
On May 16, 2006, The FDA announced that the product label for Advair has been updated with a warning that the drug might well increase the chance of severe asthma attacks that can result in death.

Side effects of Advair may consist of the following: bronchitis, cough, vomiting, diarrhea, difficulty speaking, fungal infection of the mouth, headaches, stomach pain, hoarseness, muscle and bone pain, nausea, sore throat and sinus pain.

If you or a loved one took Advair and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
AdvairRSS Feed

FDA Seeks to Limit Use of Serevent, Advair, Symbicort and Foradil

Feb 19, 2010 | Parker Waichman Alonso LLP
U.S. regulators want to limit the use of Serevent, Advair, Symbicort and Foradil.  The four drugs, part of a class of asthma medications known as long-acting beta agonists (LABAs), are being subjected to new restrictions, the U.S. Food & Drug Administration (FDA) has announced. These drugs are approved to treat both people with asthma or with chronic obstructive pulmonary disease (COPD). The new recommendations announced by the FDA only apply to the use of LABAs in the treatment of...

Advair, Symbicort Up Pneumonia Risks for COPD Sufferers

Feb 11, 2009 | Parker Waichman Alonso LLP
Advair, Symbicort and other inhaled corticosteroids may increase the risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) by as much as 70%, according to a news study.   The study, conducted by researchers at Wake Forest University Baptist Medical Center, was published in the Feb. 9 issue of the Archives of Internal Medicine.Advair, and Symbicort are known as long-acting beta-agonists (LABA), a class of drugs used to treat asthma.  Both Advair and...

FDA Panel Wants Restrictions on Two Asthma Drugs

Dec 12, 2008 | Parker Waichman Alonso LLP
A U.S. Food and Drug Administration (FDA) panel has called for restrictions on two asthma treatments:  Serevent and Foradil.  Both belong to a class  of drugs known as long-acting beta-agonists.  Both contain a drug that relaxes muscles around airways, said WHEC TV, but may also mask symptoms that can prompt deadly asthma attacks.  Although the expert 27-member panel found Serevent and Foradil drugs present greater risks than benefits and should not be used in the...

FDA Considers Heart Risks of Serevent, Foradil, Advair and Symbicort

Dec 11, 2008 | Parker Waichman Alonso LLP
One expert estimates that long-acting beta-agonists (LABAs)  - a class of asthma drugs that includes Serevent, Foradil, Advair, and Symbicort - might be responsible for about 14,000 deaths, Reuters is reporting.  The comments were part of a confrontational meeting between the U.S. Food and Drug Administration (FDA) and an advisory panel discussing how to handle increased risks experienced with the inhaled asthma medications called LABAs, said Reuters, LABAs are used by millions of...

Complications, Deaths Seen with Some Long-Acting Asthma Drugs

Dec 5, 2008 | Parker Waichman Alonso LLP
Some asthma drugs in a class  known as long-acting beta agonists (LABA) can increase the risk of death and complications, a new Food & Drug Administration (FDA) analysis has found.  The analysis looked at GlaxoSmithKline PLC's Serevent and Advair, Novartis AG's and Schering-Plough Corp.'s Foradil and AstraZeneca PLC's Symbicort.The FDA analysis was prepared for an advisory committee meeting next week that is slated to discuss the safety of the drugs, The Wall Street Journal...

More Advair News